fbpx
Big Law

Roche Resolves a U.S. Patent Lawsuit Against Biogen Over Its Blockbuster Arthritis Drug

Swiss pharmaceutical company Roche has settled a patent lawsuit against U.S. biotech firm Biogen over its biosimilar version of Roche’s blockbuster rheumatoid arthritis drug Actemra, according to a filing on Monday in Massachusetts federal court.

Roche and its subsidiaries Genentech and Chugai Pharmaceutical jointly told the court without providing further details that they, Biogen and its manufacturer Bio-Thera had agreed to settle the case.

A spokesperson for Genentech declined to comment. Representatives for Biogen and Bio-Thera did not immediately respond to requests for comment.

Read the source article at Yahoo Finance

Back to top button